On December 16, 2021 Kinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, reported that it has been selected for addition to the NASDAQ Biotechnology Index ("NBI") (Press release, Kinnate Biopharma, DEC 16, 2021, View Source [SID1234597304]). Kinnate’s addition to the NBI will become effective prior to market open on Monday, December 20, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The NBI is designed to track the performance of a set of securities listed on The NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical companies, and is a modified market capitalization weighted index. The NBI is reconstituted annually in December in accordance with a set of eligibility criteria including minimum market capitalization and average daily trading volume, among other criteria.

"We are pleased to be added to the NASDAQ Biotechnology Index and see it as reflection of the progress we have made this year," said Nima Farzan, Chief Executive Officer of Kinnate. "2021 has been transformative for Kinnate and the inclusion in this index will enable greater awareness about Kinnate’s mission and pipeline."